Breast Cancer Research and Treatment **33**: 275-276, 1995.

Author index, Volume 33

Abel KJ 95,115
Adlercreutz H 19
Amoroso D 265
Azli N 39
Azuma C 89

Balestrero M 265
Barreca A 219
Bayssas M 39
Bell CD 147
Bell JA 137
Berghmans K 209
Blamey RW 137
Boccardo F 219,265
Boccuzzi G 171
Boyd NF 63
Brandt R 103
Brema F 265
Brignardello E 171
Brody LC 115
Brookes S 125
Brünner N 199
Brzezinski A 257

Cassoni P 171
Castilla L 115
Catton P 63
Cellerino R 265
Chevallier B 39
Chiang H-S 225
Ciardiello F 103
Clark GM 199
Clark RM 63
Clarke R 209
Cohen JS 209
Cohen M 257
Collins FS 95,115
Couch FJ 115
Cowan KH 27
Crepin M 189

Danø K 199
De Franchis V 219
de Waard F 55
de Weger RA 245
DeBoer G 63
Demers LM 19
Di Monaco M 171
Diamond A 95
Dickson S 125
Dieras V 39
Donehower RC 1
Dorant E 163

Ellis IO 137
Elston CW 137
Ermellino L 179

Fantl V 125
Farris A 265
Folco U 265
Frigo B 179
Fujibayashi M 269
Fukuoka H 83
Fumoleau P 39

Galea MH 137
Goldbohm RA 163
Goodwin PJ 63
Grøndahl-Hansen J 199
Guan XY 95
Guillot C 189

Haga S 269
Haile RW 75
Harvey H 19
Hennipman A 245
Hood N 63
Høyer-Hansen G 199
Huang T-F 225

Iacobelli S 265
Imamura H 269
Inaji H 89
Itoh Y 83
Iwase H 83
Iwata H 83

Kajiwara T 269
Kaplan O 209
Kennedy MJ 1
Kerbrat P 39
Kinoshita J 269
Kobayashi K 269
Kobayashi S 83
Koyama H 89
Krol A 55
Kuzushima T 83

Labrie C 237
Labrie F 237
Laroye GJ 147
Lefebvre MF 189
Lévesque C 237
Li S 237
Lippman ME 209
Lipton A 19

Manzari A 179
Masamura S 19
Masaoka A 83
Massobrio M 171
Matthyssen MMM 55
Meltzer P 95
Merajver S 115
Mérand Y 237
Mesiti M 265
Migliardi M 171
Miglietta L 265
Minuto F 219
Motomura K 89

Naitoh A 83
Nicolo G 219
Noguchi S 89
Nomura Y 47
Normanno N 103

O'Donoghue AEMA 137
O'Reilly S 1
O'Shaughnessy JA 27

Osaki A 47
Osborne CK 199
Ottenhoff-Kalff AE 245

Paganini-Hill A 75
Pedersen H 199
Peeters PHM 55
Pensa F 219
Peters G 125
Pilotti S 179
Pizzini A 171
Poller DN 137

Rank F 199
Redwood S 63
Rijksen G 245
Rilke F 179
Rønne E 199
Rowinsky EK 1
Ruiz-Cabello J 209

Saez S 189
Salomon DS 103
Santen RJ 19
Santner SJ 19
Shimizu T 269
Shoyab M 103
Siemiatycki J 75
Small RA 257
Smith R 125
Staal GEJ 245
Swaim MW 225

Tashiro H 47
Thompson WD 75
Tischler EM 147
Todaro GJ 103
Torrisi R 219
Trent JM 95

Ursin G 75

Valenti G 219
van den Brandt PA 163

Van Glabbeke M 39
van Oirschot BA 245
Verbeek ALM 55

Watanabe O 269
Weber BL 95,115

Yamashita T 83

Zanardi S 219
Zhang J 95
Zurrida S 179

Breast Cancer Research and Treatment **33**: 277-280, 1995.

Subject index, Volume 33

adreno-oophorectomy
  factors predicting response and survival 47-54
age at menarche
  a breast cancer risk factor in nulliparous women 55-61
amphiregulin
  autocrine/juxtacrine growth factor in transformed breast cells 103-114
angiogenesis
  intravenous digital subtraction angiography correlates with Factor VIII staining 269-273
antiestrogens
  pure steroidal: EM-170 inhibition of rat DMBA tumor growth 237-244
aromatase inhibitors
  in endocrine therapy (review) 19-26
autocrine growth factors
  amphiregulin in breast cancer 103-114

BCA225
  serum marker elevated in recurrence 83-88
benign breast disease
  cyst fluid EGF content and proliferative pathologies 219-224
bilateral premenopausal breast cancer
  no association with early adult body weight 75-82
body mass
  see obesity
BRCA1 breast/ovarian cancer susceptibility gene
  microclone library 95-102
  transcript identification in candidate region 115-124
breast cyst fluid
  EGF content with proliferative pathologies 219-224

c-*erbB-2*
  amplification detected by PCR in nipple discharge 89-92
CA15-3
  serum marker elevated in recurrence 83-88
camptothecin 11 (CPT 11)
  role in chemotherapy (review) 1-17
carcinoembryonic antigen (CEA)
  pCEA as an indicator of poor differentiation 147-162
  serum marker elevated in recurrence 83-88
cathepsin D
  adverse prognosis with stromal expression 137-145
CGS 20267
  aromatase inhibitor, in endocrine therapy 19-26
chemotherapy
  docetaxel (Taxotere) trials 39-46
  new agents (minisymposium) 1-46
  paclitaxel (Taxol) combinations 27-37
  role of topoisomerase 1 inhibitors 1-17
  role of vinorelbine (review) 1-17
chromosome 11q13 markers
  cyclin D1 the probable key gene 125-135
chromosome microdissection
  and chromosome region-specific cDNA libraries 95-102
contraceptives
  hypothesis that melatonin addition to progestin contraceptives will prevent breast cancer 257-264
cyclical mastopathy
  a risk factor in premenopausal women 63-73
cyclin D1
  probable key oncogene on 11q13 amplicon 125-135

dehydroepiandrosterone (DHEA)
  plasma source of high breast concentrations 171-177
DHEA sulfatase
  not related to DHEA breast cancer concentrations 171-177
diet
  no effect of onion, leek, or garlic supplement intake on breast cancer incidence 163-170

diet (continued)
separated from cyclical mastopathy as a risk factor 63-73
differentiation
keratins, vimentin, and CEA as indicators 147-162
DMBA-induced rat mammary tumors
inhibition by EM-170, a pure steroidal antiestrogen 237-244
docetaxel
chemotherapy in anthracycline resistant patients 39-46
toxicity 39-46
drug resistance
P-glycoprotein blockers in paclitaxel (Taxol) treatment 27-37

EGF
content in cyst fluid vs. proliferative pathologies 219-224
EGF receptor
target for amphiregulin 103-114
endocrine therapy
aromatase inhibitors (review) 19-26
interferon α2a does not enhance megestrol acetate response 265-268
predictors of response and survival after adreno-oophorectomy 47-54
epidermal growth factor
see EGF
estrogen receptor
predictor of response and survival after adreno-oophorectomy 47-54
reliability of IHC assay on fine needle aspirates 179-184
estrogens
effects on ^{31}P NMR bioenergetic spectra 209-217
regulation of amphiregulin 103-114
exon amplification
in cloning of genes from the *BRCA1* candidate region 115-124

fibroblasts
coculture model and paracrine support of breast cancer cell growth 189-197
fine needle aspirates
reliability of ER/PgR assays by IHC 179-184

garlic supplements
no effect on breast cancer incidence 163-170
gene amplification
11q13 amplicon and the cyclin D1 gene 125-135
PCR detection in nipple discharge 89-92
genes
chromosome microdissection and physical mapping 95-102
gross cystic disease
cyst fluid EGF content and proliferative pathologies 219-224

hormonal therapy
see endocrine therapy
hormone dependence
and estrogen and tamoxifen effects on ^{31}P NMR bioenergetic spectra 209-217

immunocytochemistry
reliability of ER/PgR assays on fine needle aspirates 179-184
immunohistochemistry
adverse prognosis with stromal cathepsin D 137-145
keratins, vimentin, and CEA as indicators of differentiation 147-162
interferon α2a
no enhancement of megestrol acetate response 265-268
invasion
uPA receptor ELISA method; correlations with uPA and PAI-1 199-207

keratins, low molecular weight
an indicator of better differentiation 147-162

leek intake
no effect on breast cancer incidence 163-170
lymph node positivity
correlation with membrane protein tyrosine phosphatase activity 245-256

macrophages, stromal
cathepsin D staining and adverse prognosis 137-145
mastopathy, cyclical
a risk factor in premenopausal women 63-73

megestrol acetate
interferon α2a does not enhance response 265-268
melatonin
hypothesis that addition to progestin contraceptives will prevent breast cancer 257-264
menarche
age at, as a breast cancer risk factor in nulliparous women 55-61
mesenchyme
fibroblast coculture model and paracrine support of breast cancer cell growth 189-197
metastatic potential
correlation with membrane protein tyrosine phosphatase activity 245-256
microvessels
intravenous digital subtraction angiography correlates with Factor VIII staining 269-273
minisymposia
molecular genetics in breast cancer 95-135
new agents in breast cancer 1-46
mitotic index
correlation with cytosol protein tyrosine phosphatase activity 245-256

Navelbine
see vinorelbine
nipple discharge
PCR detection of c-erbB-2 gene amplification in 89-92
NMR spectroscopy
^{31}P bioenergetic spectra: estrogen and tamoxifen effects and hormone dependence 209-217
nulliparous women
age at menarche as a breast cancer risk factor 55-61

obesity, early adult
no association with bilateral premenopausal breast cancer 75-82
oncogenes
11q13 amplicon and the cyclin D1 gene 125-135
PCR detection of c-erbB-2 gene amplification in nipple discharge 89-92
onion intake
no effect on breast cancer incidence 163-170
oral contraceptives
hypothesis that melatonin addition to progestin contraceptives will prevent breast cancer 257-264

paclitaxel
combinations in chemotherapy 27-37
paracrine interactions
fibroblast coculture model and support of breast cancer cell growth 189-197
parity
age at menarche a breast cancer risk factor in nulliparous women 55-61
peptides, Arg-Gly-Asp (RGD)-containing
inhibition of tumor-induced platelet aggregation 225-235
phosphotyrosine
tyrosine phosphatase activity and mitotic index, metastatic potential 245-256
platelet aggregation
tumor cell induction; RGD peptide inhibition 225-235
polymerase chain reaction (PCR)
detection of c-erbB-2 gene amplification in nipple discharge 89-92
premenopausal bilateral breast cancer
no association with early adult body weight 75-82
progesterone receptor
reliability of IHC assay on fine needle aspirates 179-184
progestins
hypothesis that melatonin addition to progestin contraceptives will prevent breast cancer 257-264
interferon α2a does not enhance megestrol acetate treatment response 265-268
prognostic factors
cathepsin D in stromal cells 137-145
predictors of response and survival after adreno-oophorectomy 47-54
uPA receptor ELISA method; correlations with uPA and PAI-1 199-207
protein tyrosine phosphatase
and mitotic index, metastatic potential 245-256
pure steroidal antiestrogens
EM-170 inhibition of rat DMBA tumor growth 237-244

Quetelet index
see obesity

recurrence
and elevated serum markers CA15-3, CEA, and BCA225 83-88
risk factors
age at menarche in nulliparous women 55-61
cyclical mastopathy in premenopausal women 63-73

serum markers
elevation of CA15-3, CEA, and BCA225 in recurrence 83-88
snake venom peptides
RGD peptides trigramin, rhodosomin block tumor-induced platelet aggregation 225-235
stromal cells
cathepsin D staining and adverse prognosis 137-145
stromal invasion
trabecular mode as an indicator of better differentiation 147-162

tamoxifen
effects on ^{31}P NMR bioenergetic spectra 209-217
Taxol
see paclitaxel
Taxotere
see docetaxel
topoisomerase 1 inhibitors
role of CPT-11 and topotecan in chemotherapy 1-17
topotecan
role in chemotherapy (review) 1-17
tumor suppressor genes
cloning of genes from the *BRCA1* candidate region 115-124
tyrosine phosphatase activity
and mitotic index, metastatic potential 245-256

urokinase plasminogen activator (uPA) receptor
sensitive ELISA assay method; correlations with uPA and PAI-1 199-207

vascularity
intravenous digital subtraction angiography correlates with Factor VIII staining 269-273
vimentin
an indicator of poor differentiation 147-162
vinorelbine
role in chemotherapy (review) 1-17
vitamin D
$1,25(OH)_2$ as a negative regulator of breast cancer cell growth 189-197